Please login to the form below

Not currently logged in
Email:
Password:

Merck ends Alzheimer’s deal, partners with Exelixis

Terminates agreement with Acumen and switches focus to R&D programme for inflammation and oncology

Merck & Co has terminated an agreement with Acumen to develop treatments for Alzheimer's disease the same day it announced it has bought the licence to an R&D programme from Exelixis.

US biotech Acumen said Merck abandoned the Alzheimer's agreement due to 'internal strategic priorities'.

The deal, originally agreed in 2003, was to develop and commercialise anti-ADDL antibody therapeutics.

Recent pre-clinical development of compounds had seen failures of a gamma secretase inhibitor, however, and little success had been seen in the efficacy of non-selective amyloid beta immunotherapies, according to Dr Franz Hefti, Acumen's newly announced president and CEO.

Despite Merck's decision to pull out of the deal, Hefti was still positive about the programme's potential.

He said: "Our Merck colleagues successfully advanced anti-ADDL antibody therapeutics to a late pre-clinical development stage based on antibodies that we believe will allow Acumen to develop a best in class, disease modifying therapy for Alzheimer's disease."

Separately, Merck is to enter a deal with Exelixis to gain exclusive worldwide licence to its PI3K-delta R&D programme.

Exelixis, another US biotech, will receive an upfront payment of $12m from Merck and will be eligible for potential development and regulatory milestone payments of up to $239m. Sales milestones are also available.

The programme covers several therapeutic areas, including inflammation and oncology.

Products in development as part of the programme include PI3K-delta inhibitor XL499.

The compounds aims to control the PI3K-delta kinase, overactivation of which is thought to lead to multiple inflammatory and allergic disorders, and certain forms of lymphona.

Dr Don Nicholson, vice president and head of Worldwide Discovery, Respiratory and Immunology Franchise, Merck Research Laboratories, said: “Exelixis has established a strong reputation for innovation in the development of targeted kinase inhibitors.

“Collaborations like this are an important part of our strategy as we seek new ways to address unmet needs in inflammatory disease and oncology.”

22nd December 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics